Literature DB >> 2049469

Low-dose aclarubicin in blastic transformation of essential thrombocythemia.

Y Asano1, Y Naritomi, H Kimura, Y Maeda, T Kusaba, S Yoshizawa, G Shiraishi.   

Abstract

We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2049469     DOI： 10.1007/bf01703149

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  8 in total

1.  New antitumor antibiotics aclacinomycins A and B.

Authors:  T Oki; Y Matsuzawa; A Yoshimoto; K Numata; I Kitamura
Journal:  J Antibiot (Tokyo)       Date:  1975-10       Impact factor: 2.649

2.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.

Authors:  S Murphy; H Iland; D Rosenthal; J Laszlo
Journal:  Semin Hematol       Date:  1986-07       Impact factor: 3.851

3.  Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin.

Authors:  T Shibuya; T Teshima; M Harada; S Taniguchi; T Okamura; S Okamura; Y Niho
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

4.  Beneficial treatment with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in a patient with primary myelofibrosis.

Authors:  Y Asano; M Shimokawa; H Okabe; H Sanefuji; K Kato
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

5.  Essential thrombocythemias. Clinical evolutionary and biological data.

Authors:  S Bellucci; M Janvier; G Tobelem; G Flandrin; Y Charpak; R Berger; M Boiron
Journal:  Cancer       Date:  1986-12-01       Impact factor: 6.860

6.  Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A.

Authors:  M Sakurai; K Sampi; M Hozumi
Journal:  Leuk Res       Date:  1983       Impact factor: 3.156

7.  Phase II study of aclarubicin in acute myeloblastic leukemia.

Authors:  D C Case; T J Ervin; M A Boyd; L G Bove; H L Sonneborn; S D Paul
Journal:  Am J Clin Oncol       Date:  1987-12       Impact factor: 2.339

8.  Essential thrombocythemia and leukemic transformation.

Authors:  S M Sedlacek; J L Curtis; J Weintraub; J Levin
Journal:  Medicine (Baltimore)       Date:  1986-11       Impact factor: 1.889
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.